Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer

被引:0
|
作者
R Shakya
G A Tarulli
L Sheng
N A Lokman
C Ricciardelli
K I Pishas
C I Selinger
M R J Kohonen-Corish
W A Cooper
A G Turner
P M Neilsen
D F Callen
机构
[1] Centre for Personalised Cancer Medicine,
[2] Cancer Therapeutics Laboratory,undefined
[3] School of Medicine,undefined
[4] Faculty of Health Sciences,undefined
[5] The University of Adelaide,undefined
[6] Dame Roma Mitchell Cancer Research Laboratories (DRMCRL),undefined
[7] School of Medicine,undefined
[8] Faculty of Health Sciences,undefined
[9] The University of Adelaide,undefined
[10] Discipline of Obstetrics and Gynaecology,undefined
[11] School of Medicine,undefined
[12] Faculty of Health Sciences,undefined
[13] Robinson Research Institute,undefined
[14] The University of Adelaide,undefined
[15] Adelaide Proteomics Centre,undefined
[16] School of Molecular and Biological Sciences,undefined
[17] The University of Adelaide,undefined
[18] Royal Prince Alfred Hospital,undefined
[19] The Kinghorn Cancer Centre,undefined
[20] Garvan Institute of Medical Research,undefined
[21] St Vincent's Clinical School,undefined
[22] UNSW Australia,undefined
[23] School of Medicine,undefined
[24] University of Western Sydney,undefined
[25] Parramatta,undefined
[26] New South Wales,undefined
[27] Australia,undefined
[28] Tissue Pathology and Diagnostic Oncology,undefined
[29] Royal Prince Alfred Hospital,undefined
[30] Sydney Medical School,undefined
[31] University of Sydney,undefined
[32] Swinburne University of Technology Sarawak Campus,undefined
来源
Oncogene | 2017年 / 36卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Missense mutations in the TP53 tumor-suppressor gene inactivate its antitumorigenic properties and endow the incipient cells with newly acquired oncogenic properties that drive invasion and metastasis. Although the oncogenic effect of mutant p53 transcriptome has been widely acknowledged, the global influence of mutant p53 on cancer cell proteome remains to be fully elucidated. Here, we show that mutant p53 drives the release of invasive extracellular factors (the ‘secretome’) that facilitates the invasion of lung cancer cell lines. Proteomic characterization of the secretome from mutant p53-inducible H1299 human non-small cell lung cancer cell line discovered that the mutant p53 drives its oncogenic pathways through modulating the gene expression of numerous targets that are subsequently secreted from the cells. Of these genes, alpha-1 antitrypsin (A1AT) was identified as a critical effector of mutant p53 that drives invasion in vitro and in vivo, together with induction of epithelial–mesenchymal transition markers expression. Mutant p53 upregulated A1AT transcriptionally through the involvement with its family member p63. Conditioned medium containing secreted A1AT enhanced cell invasion, while an A1AT-blocking antibody attenuated the mutant p53-driven migration and invasion. Importantly, high A1AT expression correlated with increased tumor stage, elevated p53 staining and shorter overall survival in lung adenocarcinoma patients. Collectively, these findings suggest that A1AT is an indispensable target of mutant p53 with prognostic and therapeutic potential in mutant p53-expressing tumors.
引用
收藏
页码:4469 / 4480
页数:11
相关论文
共 50 条
  • [31] MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases
    deKant, E
    Heide, I
    Thiede, C
    Herrmann, R
    Rochlitz, CF
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1996, 122 (11) : 671 - 675
  • [32] Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population
    Topic, Aleksandra S.
    Jelic-Ivanovic, Zorana D.
    Spasojevic-Kalimanovska, Vesna V.
    Spasic, Slavica M.
    ARCHIVES OF MEDICAL RESEARCH, 2006, 37 (07) : 866 - 870
  • [33] Alpha-1 antitrypsin deficiency: From the lung to the heart?
    Curjuric, Ivan
    Imboden, Medea
    Bettschart, Robert
    Caviezel, Seraina
    Dratva, Julia
    Pons, Marco
    Rothe, Thomas
    Schmidt-Trucksass, Arno
    Stolz, Daiana
    Thun, Gian Andri
    von Eckardstein, Arnold
    Kronenberg, Florian
    Ferrarotti, Ilaria
    Probst-Hensch, Nicole M.
    ATHEROSCLEROSIS, 2018, 270 : 166 - 172
  • [34] REVERSIBLE P53 EXPRESSION IN LUNG-CANCER
    PEZZELLA, F
    TURLEY, H
    KUZU, I
    GATTER, KC
    MASON, DY
    HARRIS, A
    LANCET, 1992, 340 (8824): : 922 - 922
  • [35] Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
    Konen, Jessica M.
    Rodriguez, B. Leticia
    Fradette, Jared J.
    Gibson, Laura
    Davis, Denali
    Minelli, Rosalba
    Peoples, Michael D.
    Kovacs, Jeffrey
    Carugo, Alessandro
    Bristow, Christopher
    Heffernan, Timothy
    Gibbons, Don L.
    CANCERS, 2019, 11 (04):
  • [36] Serum levels of alpha-1 antitrypsin predict phenotypic expression of the alpha-1 antitrypsin gene in the pediatric population.
    Steiner, SJ
    Gupta, SK
    Croffie, JM
    Chong, SKF
    Fitzgerald, JF
    GASTROENTEROLOGY, 1998, 114 (04) : A1345 - A1345
  • [37] Pontin, a new mutant p53 binding protein, promotes gain-of-function of mutant p53
    Zhao, Yuhan
    Zhang, Cen
    Yue, Xuetian
    Li, Xiaoyan
    Liu, Juan
    Yu, Haiyang
    Yang, Qifeng
    Feng, Zhaohui
    Hu, Wenwei
    CANCER RESEARCH, 2015, 75
  • [38] Mutant p53 in colon cancer
    Nakayama, Mizuho
    Oshima, Masanobu
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (04) : 267 - 276
  • [39] UBE1C is upregulated and promotes neddylation of p53 in lung cancer
    Liu, Hsun
    Shih, Yung-Hsin
    Wang, Wen-Lun
    Chang, Wei-Lun
    Wang, Yi-Ching
    FASEB JOURNAL, 2023, 37 (10):
  • [40] The Expression of Hypoxia Inducible Factor 1-alpha in Lung Cancer and Its Correlation with P53 and VEGF
    张惠兰
    张珍祥
    徐永健
    邢丽华
    刘剑波
    郦俊
    谭庆
    华中科技大学学报(医学英德文版), 2004, (02) : 124 - 127